
'Flimsy or poorly thought-out applications of AI can lead to unnecessary job losses'
Over this 10-year journey at the helm, what were the top three challenges you faced?
I came in during a storm — the MAGGI controversy, which was a major challenge. Then came COVID, which disrupted supply chains and raised serious concerns around employee safety. The third was the recent sugar controversy.
Tell us how you managed to regain consumer confidence after the MAGGI and the sugar controversy.
MAGGI is a deeply loved brand. The allegations of high lead content were shocking and struck at the heart of food quality and safety. I reached out to regulators, authorities, and the media to explain our stance and reassure the public about our commitment to safety. We went to the Bombay High Court, which allowed us to retest and relaunch. The brand went from being a market leader to completely off shelves and then back to leadership in record time.
The sugar controversy stemmed from allegations by a Swiss NGO, which claimed we had different standards for developing and developed markets. We clarified that this was not true — products with added or no refined sugar are sold globally, and all our products meet and exceed FSSAI standards. The allegation did momentarily hurt the brand, but we had already been working on no-refined-sugar products.
How do you deal with the rise of influencers criticising packaged foods?
There are two phenomena – innocence of ignorance and fake news. Not everyone is a nutrition expert, and that's understandable. But fake news is deliberate and dangerous. There's a lot of half-understanding of nutrition, and this can seriously harm the industry if left unchecked. It's not just religion or politics that suffer from fake news—nutrition is probably a close third in terms of online misinformation. The solution to ignorance is to accentuate the truth. Vilifying or going after influencers doesn't help.
Have these events prompted a rethink of your product portfolio?
We continuously work on improving the nutritional profile of our products. Over the past 5–6 years, we have significantly reduced salt, sugar, and fats across the portfolio. The challenge is balancing taste and nutrition — nobody wants a healthy but tasteless product.
Looking back, what are the biggest achievements under your leadership?
In terms of financial performance, in 10 years, turnover grew 2.5x, net profit 6x, market cap 4x, and shareholder count 7x. RoE rose from 19% to 89%. We've also split shares and declared a 1:1 bonus issue.
Diversity and inclusion is another area I am proud of. When I joined, only 10% of leadership were women. Today, it's 20%. A quarter of our frontline sales force is female.
A third significant achievement is in sustainability. Our coffee and spices are sustainably sourced, and we pay extra to farmers who adopt sustainable practices. We have cut water usage by 50% and achieved plastic neutrality.
What is your view on AI's impact on jobs in the FMCG sector?
Technology should be a tool to enhance progress and prosperity—not the other way around. We are selective in our use of AI and are developing use cases across planning, logistics, automation, and manufacturing excellence.
These use cases will be gradually deployed where there's a direct impact on business growth, productivity, or cost. We're not taking a random approach to automation. Instead, we follow a roadmap—especially for forecasting and supply chain models.
Do you think there is a need to regulate the adoption of AI?
I believe regulation should be based on the use case. Flimsy or poorly thought-out applications of AI can lead to unnecessary job losses. We need clear protocols to prevent such outcomes.
How do you think the threat of Trump tariffs would play out for the Indian economy and the FMCG sector?
India's strength lies in domestic consumption, which makes up two-thirds of our GDP. With inflation easing, infrastructure expanding, and tax reliefs announced, consumption is reviving. India remains one of the most economically robust geographies, especially given global volatility. With 1.4 billion consumers, there's really no parallel.
Recently, you added pet food. What more can we expect from Nestlé's portfolio?
Our four core categories—prepared dishes, confectionery, dairy & nutrition, and chocolate—still have strong growth potential. We have added Pet Care to our basket. With 25-30 million pets in India, growing at 10% annually, and only 5% using complementary feeding, the potential is immense. The premium coffee segment with Nespresso is growing rapidly, and Nestlé Health Science is another new addition. Our JV with Dr. Reddy's focuses on health and wellness products. These are strong pillars and seeds for future growth.
Will Nestlé ever venture into the cola business?
No. Nestlé focuses on nutrition-based, differentiated products that leverage science and technology. You won't see us in the atta-chawal business, nor in cola.
Any regrets?
One of my regrets is that we haven't made any acquisitions during my tenure. We did enter into a joint venture with Dr. Reddy's, but no outright acquisitions. That said, if there's a good fit in terms of business, culture, and commercial alignment with Nestlé, the company would certainly be interested.
While I've developed a strong local team and nurtured local talent, I wish I had given more of them leadership opportunities. There's always that feeling—I could have done more to leverage local leadership.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
an hour ago
- The Hindu
KTU decides to waive year-out system for UG programmes this year
APJ Abdul Kalam Technological University (KTU) has decided to waive the year-out system for all undergraduate programmes for the present academic year. The minimum credit requirement for promotion to the fifth and seventh semesters has been waived following representations from student organisations and affiliated colleges. The issue, which potentially affected several students under the 2019 regulations, had triggered protests recently. Students were required to earn a minimum of 21 out of 38 credits from the first two semesters to be eligible for promotion to the fifth semester and 47 out of 82 credits from the first four semesters to advance to the seventh semester. Numerous petitions While these criteria had been temporarily suspended during the COVID-19 pandemic, they were reinstated in the 2023-24 academic year. However, this year, the university received numerous petitions from stakeholders, citing the difficulties faced by a substantial number of students who remain ineligible for promotion due to credit shortfalls. An analysis by the KTU's Academics Branch revealed that around 4,208 BTech students at present fell short of the required credits for seventh-semester registration. Besides, 6,428 students were ineligible for the fifth semester. These figures represent nearly 15% and 20% from the respective BTech batches. Students unable to progress to the fifth semester would require to transition to the revised 2024 curriculum, leading to additional academic burden due to transitory course requirements. Other students too The university also found that students from other undergraduate programmes face similar risks of losing academic continuity due to unmet credit requirements. The decision to waive the minimum credit requirement for promotion to the higher semesters will be subsequently reported at the upcoming meetings of the Academic Council and the Board of Governors.


Mint
2 hours ago
- Mint
Pfizer Q2 Results: Pharma major's sales jump to $14.65 billion; firm raises profit forecast for 2025 over cost cuts
Aug 5 (Reuters) - Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as it expects to benefit from its cost-cutting efforts and a weaker dollar. The company said the new forecast absorbs a one-time charge of 20 cents per share related to its licensing deal with China's 3SBio for experimental cancer treatment. Shares of the New York-based company rose 2.8% to $24.19 in premarket trading. The company's shares have lost more than half their value from their pandemic-era highs as the drugmaker deals with waning revenue from COVID products and looming patent expirations for key drugs. In response, the company launched cost-saving measures last year across its manufacturing and research operations. Pfizer said it was on track to deliver $7.2 billion in net savings from the programs by the end of 2027, out of which about $4.5 billion will be delivered by the end of 2025. J.P. Morgan analyst Chris Schott said that the quarterly beat and the forecast raise did not come as a surprise given the company's better-than-expected cost management. "We would not be surprised with additional upside to EPS as the year progresses," Schott said. The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80 to $3.00 per share. Total quarterly sales topped estimates by $1 billion and came in at $14.65 billion, including a $22 million favorable impact from foreign exchange. Revenue from Pfizer's antiviral treatment, Paxlovid, was $427 million for the quarter, compared with analysts' expectations of $244.4 million. COVID vaccine Comirnaty, which Pfizer makes with German partner BioNTech, brought in sales of $381 million. Analysts were expecting sales of $188 million. On an adjusted basis, Pfizer earned 78 cents per share for the second quarter, compared with analysts' expectations of 58 cents. (Reporting by Bhanvi Satija and Mrinalika Roy in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva)


Deccan Herald
3 hours ago
- Deccan Herald
Shocked by how your cozy Mac n Cheese is made at your nearby restaurant? Instant complaints are now just a scan away!
The FSSAI has asked all eateries to display their FSSAI license/registration certificate with the QR code of Food Safety Connect app in areas visible to customers.